In this work, to investigate the structure of the EGFR/RAS/RIT1 signaling network and identify therapeutic targets in lung cancer, we perform genome-wide CRISPR screens in isogenic PC9 cells where drug resistance is potently conferred by each expressed oncogene. This evidence concerns the gene EGFR and lung carcinoma.